Alemtuzumab (Amab) vs. Basiliximab (Bmab) Induction: Impact on Infectious and Non-Infectious Outcomes among Lung Transplant Patients (LT pts)

被引：1
|
作者：
Nguyen, M. H. [1 ]
Clancy, C. J. [1 ]
Crespo, M. M. [1 ]
Pilewski, J. [1 ]
Bermudez, C. [1 ]
Shigemura, N. [1 ]
Bhama, J. K. [1 ]
Johnson, B. [1 ]
Morrell, M. [1 ]
Shields, R. K. [1 ]
Kwak, E. J. [1 ]
Silveira, F. [1 ]
Toyoda, Y. [1 ]
机构：
[1] Univ Pittsburgh, Pittsburgh, PA 15260 USA
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2012年 / 31卷 / 04期
关键词：
D O I：
10.1016/j.healun.2012.01.289
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
281
引用
收藏
页码：S101 / S102
页数：2
相关论文
共 8 条
  • [1] Rates of Respiratory Viral Infection in Pediatric Lung Transplant Patients After ATG vs. Basiliximab Induction
    Henderson, C.
    Nicholas, S.
    Munoz-Rivas, F.
    Melicoff-Portillo, E.
    Das, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [2] Prospective, Randomized, Single-Center Trial of Alemtuzumab vs. Rabbit Anti-Thymocyte Globulin Induction in Renal and Pancreas Transplant: Infectious Complications Update.
    Doares, William
    Ashcraft, Elizabeth
    Singh, Rajinder
    Hart, Lois
    Farney, Alan
    Hartmann, Erica
    Reeves-Daniel, Amber
    Rogers, Jeff
    Adams, Patricia
    Stratta, Robert
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 282 - 283
  • [3] Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal
    Saull, Harrison E.
    Enderby, Cher Y.
    Gonwa, Thomas A.
    Wadei, Hani M.
    CLINICAL TRANSPLANTATION, 2015, 29 (07) : 573 - 580
  • [4] Outcomes of weight-based vs. fixed dose of Pembrolizumab among patients with non-small cell lung cancer
    Chaitesipaseut, Lena
    Shah, Nina
    Truong, Thach-Giao
    Niu, Fang
    Shin, Patrick
    Sharma, Kavita
    Smith, Joshua
    Hui, Rita L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (08) : 1352 - 1357
  • [5] Impact of Adalimumab (Humira) Therapy on Ocular Inflammation, Selected Health Care Resource Utilization, and Patient-Reported Outcomes in Patients with Active Non-infectious Intermediate, Posterior, or Panuveitis in Routine Clinical Practice
    Pleyer, Uwe
    Almutairi, Salem
    Murphy, Conor
    Hamam, Rola
    Julian, Karina
    Hammad, Shereen
    Nagy, Orsolya
    Habot-Wilner, Zohar
    Szepessy, Zsuzsanna
    Guex-Crosier, Yan
    Androudi, Sofia
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [6] Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone
    Huang, Eugene H.
    Liao, Zhongxing
    Cox, James D.
    Guerrero, Thomas M.
    Chang, Joe Y.
    Jeter, Melinda
    Borghero, Yerko
    Wei, Xiong
    Fossella, Frank
    Herbst, Roy S.
    Blumenschein, George R., Jr.
    Moran, Cesar
    Allen, Pamela K.
    Komaki, Ritsuko
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (03): : 779 - 785
  • [7] Impact of Small Cell (SC) versus (vs.) Non-Small Cell (nSC) Morphology on Outcomes of Patients (pts) with Extra-Pulmonary, Poorly Differentiated Neuroendocrine Carcinoma (EP-PD-NEC)
    Zaninotto, E.
    Frizziero, M.
    Durand, A.
    Taboada, R. G.
    Luchini, C.
    Oliveira, P.
    Hervieu, V
    Claro, L. C. L.
    Cingarlini, S.
    Walter, T.
    Riechelmann, R.
    McNamara, M.
    NEUROENDOCRINOLOGY, 2020, 110 : 244 - 244
  • [8] Outcomes of patients (pts) with disease recurrence after treatment for locally advanced non-small cell lung cancer (LANSCLC) detected by routine follow-up (f/u) CT scans vs. symptom (sx) driven evaluation.
    Bodor, Joseph Nicholas
    Feliciano, Josephine Louella
    Bentzen, Soren
    Edelman, Martin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
1